The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Primary Biliary Cholangitis Treatment Market Research Report 2024

Global Primary Biliary Cholangitis Treatment Market Research Report 2024

Publishing Date : May, 2024

License Type :
 

Report Code : 1718770

No of Pages : 72

Ask Your Query
Synopsis
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There's no cure for primary biliary cholangitis, but medications are available to help slow the progression of the disease and prevent complications. Options include: Ursodeoxycholic acid (UDCA) and Obeticholic acid (Ocaliva).
The global Primary Biliary Cholangitis Treatment market was valued at US$ 654.2 million in 2023 and is anticipated to reach US$ 1064.3 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Primary Biliary Cholangitis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Biliary Cholangitis Treatment.
Report Scope
The Primary Biliary Cholangitis Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Primary Biliary Cholangitis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Biliary Cholangitis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals
Segment by Type
Ursodeoxycholic Acid (UDCA)
Obeticholic Acid (Ocaliva)
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Primary Biliary Cholangitis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Ursodeoxycholic Acid (UDCA)
1.2.3 Obeticholic Acid (Ocaliva)
1.3 Market by Application
1.3.1 Global Primary Biliary Cholangitis Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Biliary Cholangitis Treatment Market Perspective (2019-2030)
2.2 Primary Biliary Cholangitis Treatment Growth Trends by Region
2.2.1 Global Primary Biliary Cholangitis Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Primary Biliary Cholangitis Treatment Historic Market Size by Region (2019-2024)
2.2.3 Primary Biliary Cholangitis Treatment Forecasted Market Size by Region (2025-2030)
2.3 Primary Biliary Cholangitis Treatment Market Dynamics
2.3.1 Primary Biliary Cholangitis Treatment Industry Trends
2.3.2 Primary Biliary Cholangitis Treatment Market Drivers
2.3.3 Primary Biliary Cholangitis Treatment Market Challenges
2.3.4 Primary Biliary Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Biliary Cholangitis Treatment Players by Revenue
3.1.1 Global Top Primary Biliary Cholangitis Treatment Players by Revenue (2019-2024)
3.1.2 Global Primary Biliary Cholangitis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Primary Biliary Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Biliary Cholangitis Treatment Revenue
3.4 Global Primary Biliary Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Biliary Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Biliary Cholangitis Treatment Revenue in 2023
3.5 Primary Biliary Cholangitis Treatment Key Players Head office and Area Served
3.6 Key Players Primary Biliary Cholangitis Treatment Product Solution and Service
3.7 Date of Enter into Primary Biliary Cholangitis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Biliary Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Biliary Cholangitis Treatment Historic Market Size by Type (2019-2024)
4.2 Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Type (2025-2030)
5 Primary Biliary Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Biliary Cholangitis Treatment Historic Market Size by Application (2019-2024)
5.2 Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Primary Biliary Cholangitis Treatment Market Size (2019-2030)
6.2 North America Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024)
6.4 North America Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Biliary Cholangitis Treatment Market Size (2019-2030)
7.2 Europe Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024)
7.4 Europe Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size (2019-2030)
8.2 Asia-Pacific Primary Biliary Cholangitis Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Biliary Cholangitis Treatment Market Size (2019-2030)
9.2 Latin America Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024)
9.4 Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size (2019-2030)
10.2 Middle East & Africa Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Primary Biliary Cholangitis Treatment Introduction
11.1.4 Novartis Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Introduction
11.2.4 Bristol-Myers Squibb Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Primary Biliary Cholangitis Treatment Introduction
11.3.4 Pfizer Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Primary Biliary Cholangitis Treatment Introduction
11.4.4 GlaxoSmithKline Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Teva Pharmaceutical
11.5.1 Teva Pharmaceutical Company Detail
11.5.2 Teva Pharmaceutical Business Overview
11.5.3 Teva Pharmaceutical Primary Biliary Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceutical Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.5.5 Teva Pharmaceutical Recent Development
11.6 Retrophin
11.6.1 Retrophin Company Detail
11.6.2 Retrophin Business Overview
11.6.3 Retrophin Primary Biliary Cholangitis Treatment Introduction
11.6.4 Retrophin Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.6.5 Retrophin Recent Development
11.7 Lumena Pharmaceuticals
11.7.1 Lumena Pharmaceuticals Company Detail
11.7.2 Lumena Pharmaceuticals Business Overview
11.7.3 Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Introduction
11.7.4 Lumena Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.7.5 Lumena Pharmaceuticals Recent Development
11.8 Intercept Pharmaceuticals
11.8.1 Intercept Pharmaceuticals Company Detail
11.8.2 Intercept Pharmaceuticals Business Overview
11.8.3 Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Introduction
11.8.4 Intercept Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024)
11.8.5 Intercept Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Ursodeoxycholic Acid (UDCA)
Table 3. Key Players of Obeticholic Acid (Ocaliva)
Table 4. Global Primary Biliary Cholangitis Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Primary Biliary Cholangitis Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Primary Biliary Cholangitis Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Primary Biliary Cholangitis Treatment Market Share by Region (2019-2024)
Table 8. Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Primary Biliary Cholangitis Treatment Market Share by Region (2025-2030)
Table 10. Primary Biliary Cholangitis Treatment Market Trends
Table 11. Primary Biliary Cholangitis Treatment Market Drivers
Table 12. Primary Biliary Cholangitis Treatment Market Challenges
Table 13. Primary Biliary Cholangitis Treatment Market Restraints
Table 14. Global Primary Biliary Cholangitis Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Primary Biliary Cholangitis Treatment Market Share by Players (2019-2024)
Table 16. Global Top Primary Biliary Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cholangitis Treatment as of 2023)
Table 17. Ranking of Global Top Primary Biliary Cholangitis Treatment Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Primary Biliary Cholangitis Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Primary Biliary Cholangitis Treatment Product Solution and Service
Table 21. Date of Enter into Primary Biliary Cholangitis Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Primary Biliary Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Type (2019-2024)
Table 25. Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Type (2025-2030)
Table 27. Global Primary Biliary Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Application (2019-2024)
Table 29. Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Application (2025-2030)
Table 31. North America Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 46. Novartis Company Detail
Table 47. Novartis Business Overview
Table 48. Novartis Primary Biliary Cholangitis Treatment Product
Table 49. Novartis Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 50. Novartis Recent Development
Table 51. Bristol-Myers Squibb Company Detail
Table 52. Bristol-Myers Squibb Business Overview
Table 53. Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Product
Table 54. Bristol-Myers Squibb Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 55. Bristol-Myers Squibb Recent Development
Table 56. Pfizer Company Detail
Table 57. Pfizer Business Overview
Table 58. Pfizer Primary Biliary Cholangitis Treatment Product
Table 59. Pfizer Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 60. Pfizer Recent Development
Table 61. GlaxoSmithKline Company Detail
Table 62. GlaxoSmithKline Business Overview
Table 63. GlaxoSmithKline Primary Biliary Cholangitis Treatment Product
Table 64. GlaxoSmithKline Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 65. GlaxoSmithKline Recent Development
Table 66. Teva Pharmaceutical Company Detail
Table 67. Teva Pharmaceutical Business Overview
Table 68. Teva Pharmaceutical Primary Biliary Cholangitis Treatment Product
Table 69. Teva Pharmaceutical Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 70. Teva Pharmaceutical Recent Development
Table 71. Retrophin Company Detail
Table 72. Retrophin Business Overview
Table 73. Retrophin Primary Biliary Cholangitis Treatment Product
Table 74. Retrophin Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 75. Retrophin Recent Development
Table 76. Lumena Pharmaceuticals Company Detail
Table 77. Lumena Pharmaceuticals Business Overview
Table 78. Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Product
Table 79. Lumena Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 80. Lumena Pharmaceuticals Recent Development
Table 81. Intercept Pharmaceuticals Company Detail
Table 82. Intercept Pharmaceuticals Business Overview
Table 83. Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Product
Table 84. Intercept Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 85. Intercept Pharmaceuticals Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Biliary Cholangitis Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Primary Biliary Cholangitis Treatment Market Share by Type: 2023 VS 2030
Figure 3. Ursodeoxycholic Acid (UDCA) Features
Figure 4. Obeticholic Acid (Ocaliva) Features
Figure 5. Global Primary Biliary Cholangitis Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Primary Biliary Cholangitis Treatment Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Primary Biliary Cholangitis Treatment Report Years Considered
Figure 11. Global Primary Biliary Cholangitis Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Primary Biliary Cholangitis Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Primary Biliary Cholangitis Treatment Market Share by Region: 2023 VS 2030
Figure 14. Global Primary Biliary Cholangitis Treatment Market Share by Players in 2023
Figure 15. Global Top Primary Biliary Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cholangitis Treatment as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Primary Biliary Cholangitis Treatment Revenue in 2023
Figure 17. North America Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Primary Biliary Cholangitis Treatment Market Share by Country (2019-2030)
Figure 19. United States Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Primary Biliary Cholangitis Treatment Market Share by Country (2019-2030)
Figure 23. Germany Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Primary Biliary Cholangitis Treatment Market Share by Region (2019-2030)
Figure 31. China Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Primary Biliary Cholangitis Treatment Market Share by Country (2019-2030)
Figure 39. Mexico Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Primary Biliary Cholangitis Treatment Market Share by Country (2019-2030)
Figure 43. Turkey Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Novartis Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 46. Bristol-Myers Squibb Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 47. Pfizer Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 48. GlaxoSmithKline Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 49. Teva Pharmaceutical Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 50. Retrophin Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 51. Lumena Pharmaceuticals Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 52. Intercept Pharmaceuticals Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock